



New York State Medicaid Drug Utilization Review (DUR) Board Meeting Agenda – February 13, 2020

The DUR Board will meet on February 13, 2020, from 9:00 a.m. to 4:00 p.m.
Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

A. Drug Utilization Reviews

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Management of non-acute pain - utilization of opioids and morphine milligram equivalent parameters.
2. Management of eosinophilic asthma (EA) - utilization of medications for EA and place in asthma therapy.
3. Management of Oral Second-Generation Antipsychotics (SGAs) - utilization of SGAs and maximum daily dosages.

B. Clinical Editing Updates

The DUR Board will be provided updates on the following topics and, if applicable, recommend changes to clinical editing:

1. Utilization trends for products used for the treatment of opioid use disorder.
2. Utilization trends for long-acting opioids used for the management of pain.

C. General Program Updates

The DUR Board will be provided information associated with the following initiatives and programs:

1. Medicaid Retrospective Drug Utilization Review - Fluroquinolone Project
2. Medicaid Prescriber Education Program - Antibiotic Stewardship

Agenda Timeline (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome and Opening Comments
9:15 - 10:15	Public Comment Period
10:15 - 12:30	Drug Utilization Reviews
12:30 - 1:30	Lunch/Executive Session
1:30 - 2:30	Clinical Editing Updates
2:30 - 3:45	General Program Updates
3:45 - 4:00	Final Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by February 5, 2020. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov. (please reference DUR Board Meeting speaker request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by February 5, 2020. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by January 30, 2020 or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.